Fund Holdings — Foresite Capital Management IV, LLC

Total Portfolio Value:
$197.87M
Total Bought:
$35.16M
Total Sold:
$49.12M
Net Transaction:
-$13.95M
Securities
▲▼
SharesValue
Q3 2023
▲▼
Q4 2023
▲▼
Change
▲▼
Q3 2023
▲▼
Q4 2023
▲▼
Weight (%)
▲▼
Change
▲▼
Pharvaris N.V.
COM
3,743,4504,038,842+295,392$78.13M$113.29M57.25%+$35.16M
Kura Oncology, Inc.(KURA)1,849,9471,849,9470$16.87M$26.60M13.44%+$9.73M
Kinnate Biopharma Inc.9,671,6439,671,6430$13.54M$22.92M11.58%+$9.38M
Syndax Pharmaceuticals, Inc.(SNDX)875,000875,0000$12.71M$18.91M9.56%+$6.20M
Lyell Immunopharma, Inc.(LYEL)8,784,8138,325,000-459,813$12.91M$16.15M8.16%+$3.24M
Aclaris Therapeutics, Inc.COM(ACRS)2,808,0340-2,808,034$19.24M$0—-$19.24M
Cymabay Therapeutics, Inc.COM1,787,0940-1,787,094$26.65M$0—-$26.65M
Page 1 of 1
Foresite Capital Management IV, LLC — 13F Holdings — Q4 2023 | TickerTrail